Skip to main content
Cytogen, Inc. logo

Cytogen, Inc. — Investor Relations & Filings

Ticker · 217330 ISIN · KR7217330000 KO Manufacturing
Open in API
Filings indexed 437 across all filing types
Latest filing 2023-01-25 Proxy Solicitation & In…
Country KR South Korea
Listing KO 217330

About Cytogen, Inc.

https://www.cytogenlab.com/

Cytogen, Inc. is a biotechnology company specializing in liquid biopsy platforms for precision oncology. The company has developed proprietary technology for the rapid isolation and analysis of viable Circulating Tumor Cells (CTCs) from whole blood. Its core offering, the SmartBiopsy Platform, utilizes a high-density microporous chip with microfluidics and nanotechnology to capture CTCs efficiently. This non-invasive diagnostic approach is designed to support early cancer detection, treatment monitoring, and the advancement of personalized medicine for cancer patients.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting' (주주총회소집공고) issued by Cytogen. It includes details about the meeting date, location, agenda items (such as amendments to the articles of incorporation), and instructions for electronic voting. This document is a standard proxy solicitation material provided to shareholders to inform them of an upcoming meeting and request their participation or vote, which falls under the Proxy Solicitation & Information Statement category.
2023-01-25 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting' (임시주주총회소집공고) issued by Cytogen. It contains the meeting agenda, details on voting procedures, electronic voting instructions, and proposed changes to the company's articles of incorporation. This document is a standard proxy solicitation material sent to shareholders to inform them of an upcoming meeting and request their participation/votes, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement.
2023-01-19 Korean
[기재정정]전환가액의조정(제4회차)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KRX) regarding the adjustment of the conversion price for convertible bonds (CB). This type of filing, which details changes to capital structure instruments like convertible bonds, falls under 'Capital/Financing Update' as it relates to financing activities and capital structure adjustments.
2023-01-09 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a shareholder meeting (주주총회소집결의) issued by CytoGen. It details the date, location, and agenda items (such as amendments to the articles of incorporation) for an upcoming Extraordinary General Meeting. This type of document is a standard proxy-related notification sent to shareholders to inform them of meeting logistics and voting items, which falls under the Proxy Solicitation & Information Statement category.
2023-01-02 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for a shareholder meeting (closing of the shareholder register). It is a standard corporate disclosure filed with the KRX (Korea Exchange) to inform shareholders of an upcoming Extraordinary General Meeting. Since it is a regulatory announcement that does not fit into specific categories like financial reports or proxy statements, and serves as a general regulatory disclosure, it is classified as RNS.
2023-01-02 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (CytoGen) regarding a 'Correction Report' (정정신고) for a 'Stock Collateral Agreement involving a change in the largest shareholder'. This type of disclosure is a standard regulatory requirement for listed companies to report significant changes in share ownership or collateralization status. Since it does not fit into specific categories like earnings, dividends, or M&A, and is a formal regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2022-12-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.